Change in Director / Key Managerial Personnel

Nature of change: Appointment of Chief Technology Officer and Senior Management Personnel

Name and DIN: Mr. Viral Gandhi (DIN not disclosed in the filing)

Effective date and tenure: Appointment effective from 1st October 2026. Tenure details not specified.

Brief profile and qualifications: Mr. Viral Gandhi is President and Group Chief Information Officer at Piramal Group. He is a Digital and Change leader responsible for driving tech innovation across Group entities. He has expertise in building innovative technology solutions and establishing strong technology culture to transform organizations.

Previous experience:

  • Chief Information Officer at Cox & Kings Group, driving business transformation through consumer tech solutions globally
  • Previously at Tata Consultancy Services (TCS), partnered with Fortune 100 clients including General Electric, NASDAQ, World Bank, HP, and Procter & Gamble in technology transformation journeys

Education:

  • Executive Leadership Program from Harvard Business School, USA
  • Strategy and Innovation Program from Massachusetts Institute of Technology, USA
  • Bachelor's Degree in Engineering from VJTI, Mumbai, India

Experience: Over 25 years of experience in technology and digital strategy

Awards: Conferred with several prestigious awards for contributions in technology and innovation

Relationship with directors: Mr. Gandhi is not related to any Director of the Company

Confirmation of eligibility: The appointment was approved by the Board based on the recommendation of the Nomination and Remuneration Committee, indicating compliance with SEBI/BSE/NSE norms, though specific eligibility confirmation is not explicitly stated.

Key Financial or Operational Approvals

This section does not contain information about financial or operational approvals.

Strategic or Business Context

This section does not contain strategic or business context information beyond the appointment.

Any Other Material Information

Regulatory compliance: Disclosure made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Additional information: The disclosure is also available on the company website at www.piramalpharma.com